Page 4 - Arena Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arena pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arena Pharmaceutical Today - Breaking & Trending Today

Ulcerative Colitis Market is Expected to Witness Growth at an Accelerated CAGR of 9.5% in the 7MM for the Study Period 2018-30, Assesses DelveInsight

/PRNewswire/ DelveInsight s Ulcerative Colitis Market report offers a detailed comprehension of the Ulcerative Colitis market size by treatment,. ....

United States , United Kingdom , Prnewswire Delveinsight , Theravance Biopharma Johnson , Eli Lilly , Celgene Bristol Myers Squibb , Azurrx Biopharma , Janssen Johnson , Falk Pharma Gmb , Tremfya Guselkumab , Shruti Thakur , Landos Biopharma , Falk Pharma , Skyrizi Risankizumab , Cinrx Pharma , Bristol Myers Squibb , Aptalis Pharma , Theravance Biopharma , Rinvoq Upadacitinib , Rinvoq Upadacitinib Skyrizi Risankizumab , Boehringer Ingelheim , Janssen Research Development , Hutchison Medipharma Ltd , Arena Pharmaceuticals , American Autoimmune Related Diseases Association , Gilead Sciences Galapagos ,

DelveInsight Business Research, LLP: Ulcerative Colitis Market is Expected to Witness Growth at an Accelerated CAGR of 9.5% in the 7MM for the Study Period 2018-30, Assesses DelveInsight

Targeted therapies such as Interleukin and JAK inhibitors are making inroads into the Ulcerative Colitis market owing to better clinical profile and also patient convenient dosing LAS VEGAS ....

United States , United Kingdom , Prnewswire Delveinsight , Eli Lilly , Theravance Biopharma Johnson , Celgene Bristol Myers Squibb , Azurrx Biopharma , Falk Pharma Gmb , Janssen Johnson , Tremfya Guselkumab , Shruti Thakur , Landos Biopharma , Falk Pharma , Skyrizi Risankizumab , Cinrx Pharma , Bristol Myers Squibb , Aptalis Pharma , Kostenloser Wertpapierhandel , Theravance Biopharma , Rinvoq Upadacitinib , Rinvoq Upadacitinib Skyrizi Risankizumab , Boehringer Ingelheim , Janssen Research Development , Hutchison Medipharma Ltd , Arena Pharmaceuticals , American Autoimmune Related Diseases Association ,

EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q2 Earnings Report

EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q2 Earnings Report
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Kostenloser Wertpapierhandel , Arena Pharmaceutical Inc , Arena Pharmaceutical , ஒன்றுபட்டது மாநிலங்களில் , அரங்கம் மருந்து இன்க் , அரங்கம் மருந்து ,

EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q1 Earnings Report

EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q1 Earnings Report
WASHINGTON (dpa-AFX) - Below are the earnings highlights for Arena Pharmaceutical Inc. (ARNA):
-Earnings: -$118.42 million in Q1 vs. -$100.21 million in the same period last year.
-EPS: -$1.98 in Q1 vs. -$2.00 in the same period last year.
-Analysts projected -$2.16 per share
Copyright RTT News/dpa-AFX
FNRD-2.621.0
Wie bewerten Sie die aktuell angezeigte Seite?sehr gut123456schlechtProblem melden
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen.
Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, ....

United States , Kostenloser Wertpapierhandel , Arena Pharmaceutical Inc , Arena Pharmaceutical , ஒன்றுபட்டது மாநிலங்களில் , அரங்கம் மருந்து இன்க் , அரங்கம் மருந்து ,

EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q4 Earnings Report

EARNINGS SUMMARY: Details of Arena Pharmaceutical Inc. Q4 Earnings Report
WASHINGTON (dpa-AFX) - Below are the earnings highlights for Arena Pharmaceutical Inc. (ARNA):
-Earnings: -$122.16 million in Q4 vs. -$88.31 million in the same period last year.
-EPS: -$2.10 in Q4 vs. -$1.76 in the same period last year.
-Analysts projected -$1.85 per share
-Revenue: $0.04 million in Q4 vs. $3.00 million in the same period last year.
Copyright RTT News/dpa-AFX
FNRD-2.621.0
Wie bewerten Sie die aktuell angezeigte Seite?sehr gut123456schlechtProblem melden
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. ....

United States , Kostenloser Wertpapierhandel , Arena Pharmaceutical Inc , Arena Pharmaceutical , ஒன்றுபட்டது மாநிலங்களில் , அரங்கம் மருந்து இன்க் , அரங்கம் மருந்து ,